Protection Against Omicron Up After Third Dose of Pfizer-BioNTech COVID-19 Vaccine
Findings demonstrated a 25-fold increase in neutralizing antibody titers in individuals who received the third dose.
Viral Infections
FDA Approves Livtencity for Posttransplant Cytomegalovirus
Livtencity is indicated for posttransplant CMV that does not respond to available antiviral treatments
CDC Issues Alert on Omicron Variant, Provides HCP Recommendations
The CDC is recommending that health care providers take a travel history for all suspected and confirmed cases of COVID-19.
Long-Acting Antibody Combo Reduced Risk of Symptomatic COVID-19 in Phase 3 Trials
AZD7442 is a combination of 2 long-acting monoclonal antibodies, tixagevimab and cilgavimab, derived from B-cells donated by convalescent patients who were infected with the SARS-CoV-2 virus.
FDA Panel Votes on Maribavir for Post-Transplant CMV Infection
Maribavir is an orally bioavailable anti-CMV compound that targets and inhibits the UL97 protein kinase and its natural substrates.
Posoleucel Gets Orphan Drug Status for Virus-Associated Hemorrhagic Cystitis
Posoleucel is being investigated for the treatment and prevention of serious diseases caused by 6 viral pathogens.
Long-Acting Monoclonal Antibodies Look Promising for COVID-19 Prevention
The randomized, double-blind, placebo-controlled, multicenter PROVENT trial included 5197 participants aged 18 years and older who would benefit from AZD7442.
FDA Authorizes Use of COVID-19 Antibody Therapy for Postexposure Prophylaxis
REGEN-COV consists of 2 potent, virus-neutralizing antibodies that bind noncompetitively to the receptor binding domain of the SARS-CoV-2 spike protein.
Case Series: Insulin Infusions for Severe Hypertriglyceridemia With COVID-19
Findings of the review showed that continuous insulin infusion, coupled with standard oral lipid lowering therapies, successfully treated the hypertriglyceridemia.
- Loading...
Loading...
Next post in News
Loading... 
Loading...